+

WO1992017506A1 - Modulation de l'activite de l'activateur du plasminogene tissulaire a l'aide de fragments d'heparine - Google Patents

Modulation de l'activite de l'activateur du plasminogene tissulaire a l'aide de fragments d'heparine Download PDF

Info

Publication number
WO1992017506A1
WO1992017506A1 PCT/US1992/002472 US9202472W WO9217506A1 WO 1992017506 A1 WO1992017506 A1 WO 1992017506A1 US 9202472 W US9202472 W US 9202472W WO 9217506 A1 WO9217506 A1 WO 9217506A1
Authority
WO
WIPO (PCT)
Prior art keywords
disaccharide
subunit
tpa
oligosaccharide
heparin
Prior art date
Application number
PCT/US1992/002472
Other languages
English (en)
Inventor
H. Edward Conrad
John C. Klock
Jay M. Edelberg
Salvatore V. Pizzo
Original Assignee
Glycomed, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycomed, Inc. filed Critical Glycomed, Inc.
Publication of WO1992017506A1 publication Critical patent/WO1992017506A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids

Definitions

  • the invention relates to therapeutics useful in controlling blood clots. More particularly, it concerns the use of short oligosaccharides to enhance tPA activity in blood clot dissolution, both when the tPA is administered and when endogenous tPA is relied upon.
  • Tissue plasminogen activator (tPA) is an endogenous compound which plays this important physiological role in normal subjects.
  • tPA converts plasminogen to plas in, which represents a necessary step in the cascade of events leading to fibrin dissolution.
  • the activity of tPA is, in fact, catalyzed by the presence of fibrin so that the tPA acts uniquely at the site of the blood clot to effect dissolution.
  • proteolytic enzymes which have been used for the same purpose, but which have activity independently of the presence of fibrin, include urokinase and streptokinase.
  • urokinase and streptokinase.
  • streptokinase The perceived disadvantage of these clot-dissolving drugs is that they are activated systemically, and their activity is thus quickly dissipated.
  • tPA is converted from its more stable to its activated, less stable, form only in the presence of the clot.
  • tPA is bound to heparan sulfate on clearance cells; thus, administration of heparin, or its fragments, may prevent the rapid clearance of the drug by competition with this heparan sulfate for binding.
  • administration of the competitor may enhance the concentration of endogenous tPA and may also prolong the half-life of tPA administered.
  • oligosaccharide subunits related to those present in hepa in but lacking anticoagulant activity By providing a defined composition of oligosaccharide subunits related to those present in hepa in but lacking anticoagulant activity, a more controlled regimen of tPA activity stimulation or clearance reduction can be obtained.
  • Suitable nonanticoagulant heparin fragments and disaccharides or oligosaccharides related thereto are provided by the invention.
  • the invention provides tPA activity-stimulating saccharides which can be used to enhance the activity of either endogenous or administered tPA.
  • the saccharides are either mixtures obtainable by complete nitrous acid digestion of heparin or are synthetic or purified individual saccharides, containing at least two sulfates and/or phosphates in a disaccharide unit, which lack anticoagulant activity and which, nevertheless, bind tPA and/or other fibrinolytic proteases or alter the rate constant with respect to conversion of plasminogen to plasmin.
  • the invention is directed to a pharmaceutical composition formulated for systemic, preferably oral, administration which comprises an amount of a size-fractionated fragment mixture obtainable by partial or complete heparin degradation by nitrous acid in an amount effective to maintain elevated levels of tPA activity in a subject to which the composition is administered.
  • the invention is directed to such compositions wherein the active ingredient is a disaccharide having at least two sulfate and/or phosphate moieties or a 3-12 unit oligosaccharide containing a disaccharide subunit of this type.
  • the invention is also directed to methods to enhance the dissolution of blood clots by administering the compositions of the invention and to saccharide/tPA complexes which are useful pharmaceuticals.
  • the invention methods may also involve the administration of tPA and/or other fibrinolytic agents.
  • the invention is directed to a process to prepare a sulfated and/or phosphorylated saccharide having the ability to stimulate the fibrin-dependent clot-dissolving activity of tPA.
  • the disaccharides or disaccharide subunit-containing oligosaccharide pathway of the invention may be produced synthetically using a chemical synthesis reaction as disclosed herein or may be obtained by digesting heparin and carrying out separation procedures based on size and charge as disclosed herein.
  • heparin can be obtained from a natural source and subjected to digestion with nitrous acid under conditions which favor complete digestion. Following the digestion the mixture is separated according to size and those portions corresponding to a molecular weight characteristic of di-, tetra-, hexa- and octasaccharides are segregated away and recovered. The recovered portions may then be separated according to charge in order to obtain the more highly charged portions. These portions will contain disaccharide units which contain at least two sulfate residues.
  • Figure 1 shows the elution pattern of a heparin digest from a P10 column.
  • Figure 2 shows the effect of various heparin fractions on tPA activity.
  • FIG. 3 shows the effect of lipoprotein A on the fibrinolytic reaction.
  • the invention involves systemic administration of a small heparin-related saccharide either alone or in conjunction with tPA administration.
  • a small heparin-related saccharide either alone or in conjunction with tPA administration.
  • the saccharide is administered alone, it is believed to enhance the activity of endogenous tPA and/or other endogenous fibrinolytic proteins.
  • the saccharide fragment is related to degradation products obtainable when heparin is degraded to completion using nitrous acid.
  • heparin is preferably used as the starting material.
  • heparin and heparan sulfate are members of the GAG family which are classified by the nature of the hexosamine/aldouronic acid repeating units.
  • the aldouronic acid is primarily D-glucuronic acid
  • the hexosamine is N-acetylated 2-amino-2-deoxy- D-galactose, more commonly known as N-acetyl galactosamine and abbreviated as GalNAc.
  • the aldouronic acid is mostly L-iduronic acid and the hexosamine is GalNAc.
  • the aldouronic acid is replaced by D-galactose, and the hexosamine is mostly N-acetylated 2-amino-2-deoxy-D-glucose, more commonly known as N-acetyl glucosamine and abbreviated as GlcNAc.
  • heparan sulfate and heparin the hexosamine is mostly N- acetylated or N-sulfated glucosamine (GlcNH 2 )
  • the aldouronic acid is mostly L-iduronic in heparin and mostly D-glucuronic acid in heparan sulfate.
  • Heparan sulfate is commonly considered to have a higher proportion of glucuronic acid than heparin.
  • heparin used as an anticoagulant
  • Conventional heparin has a molecular weight of 5-25 kd and is extracted as a mixture of various chain lengths by conventional procedures. These procedures involve autolysis and extraction of suitable tissues, such as beef or porcine lung, intestine or liver, and removal of other GAGs and nonpolysaccharide components.
  • the molecular weight of the chains in the extract is significantly lower than the 60-100 kDa known to exist in the polysaccharide chains of the heparin proteoglycan synthesized in the tissue.
  • the GAG moiety is synthesized bound to a peptide matrix at a serine residue through a tetrasaccharide linkage region of the sequence D-GlcA-D-Gal-D-Gal-D-Xyl ⁇ protein, which is then elongated at the D-GlcA residue with alternate additions of GlcNAc and GlcA.
  • the polysaccharide side chains are modified by a series of enzymes which sequentially deacetylate the N- acetyl glucosamine and replace the acetyl group with sulfate, epimerize the hydroxyl at C5 of the D-glucuronic acid residue (to convert it to L-iduronic acid and the GAG chain from the heparan type to a heparin type) , sulfate the 0-2 of the resulting L-iduronic acid and the 0-6 of the glucosamine residue, either at the heparan or heparin stage. This further sulfation is associated with the active site for antithrombin (anticlotting) activity. Other chemically possible sulfation sites are on the 0-2 of D-glucuronic acid; however, these are found as minor constituents.
  • D-glucuronic acid GlcA
  • L- iduronic acid IdoA
  • D-glucosamine GlcNH 2
  • N-acetyl- D-glucosamine GlcNAc
  • N-acetyl-D-galactosamine GalNAc
  • D-glucosamine N-sulfate GlcNS
  • 2,5- anhydromannose AMan
  • 2,5-anhydromannitol AManH
  • D- xylose Xyl
  • glycosa inoglycan GAG
  • acetyl Ac.
  • the location of the O-linked sulfate residues is indicated by "S” and the number of the position of sulfation where the sulfate residue is linked to oxygen on the sugar residue.
  • one or more sulfates may be replaced by phosphate; in these embodiments the phosphate is represented by "P".
  • the alpha and beta anomeric linkages are as those conventionally found in heparin, and the indicated D or L configurations, as conventionally found, pertains.
  • the locations of the sulfates are shown below the abbreviation for the sugar to which they apply; thus, for example,
  • heparin/heparan sulfate or "heparin” is meant a preparation obtained from tissues in a manner conventional for the preparation of heparin as an anti ⁇ coagulant or otherwise synthesized and corresponding to that obtained from tissue.
  • This preparation may include residues of D-glucuronic acid (GlcA) , as characteristic of heparan sulfate as well as L-iduronic acid (IdoA) as characteristic of heparin.
  • GlcA D-glucuronic acid
  • IdoA L-iduronic acid
  • the conversion of D-glucuronic acid to L-iduronic acid is a result of epimerization at the 5-carbon of GlcA in a heparan-type intermediate.
  • the "heparin/heparan sulfate" preparation can be obtained from a variety of mammalian tissues, including, if desired, human tissue. Generally, porcine or bovine sources are used, and vascularized tissue is preferred. A preferred source of heparin/heparan sulfate starting material is porcine intestinal mucosa, and preparations labeled "heparin" prepared from this tissue source are commercially available. In general, the heparin/heparan sulfate starting material is prepared from the selected tissue source by allowing the tissue to undergo autolysis and extracting the tissue with alkali, followed by coagulation of the protein, and then precipitation of the heparin-protein complex from the supernatant by acidification.
  • the complex is recovered by reprecipitation with a polar nonaqueous solvent, such as ethanol or acetone or their mixtures, and the fats are removed by extraction with an organic solvent such as ethanol and proteins by treatment with a proteolytic enzyme, such as trypsin.
  • a polar nonaqueous solvent such as ethanol or acetone or their mixtures
  • an organic solvent such as ethanol and proteins
  • proteolytic enzyme such as trypsin.
  • Suitable procedures for the preparation of the heparin starting material are found, for example, in Charles, A.F., et al., Biochem J (1936) 3J):1927-1933, and modifications of this basic procedure are also known, such as those disclosed by Coyne, E. , in Chemistry and Biology of Heparin. Elsevier Publishers, North Holland, New York, Lunblad, R.L., et al., eds. (1981) .
  • the starting material is then depolymerized with nitrous acid under conditions which effect partial or complete depolymerization.
  • nitrous acid cleaves specifically at the linkage between -lo ⁇
  • Glucosamine residues which are ' acetylated on the nitrogen provide 1,4-linkages which are resistant to nitrous acid cleavage. It is also known that the conditions of nitrous acid cleavage effect the deamination and recyclization of the sugar at the reducing terminus to obtain a 2,5-D-anhydromannose at this position.
  • the nitrous acid is generated in situ from sodium nitrite by adjusting the pH to acidic pH, preferably around pH 1.5.
  • the total nitrous acid in such a reaction mixture may be controlled by controlling the amount of sodium nitrite added, and may be in amounts either less than or greater than required for complete cleavage of all of the susceptible bonds in the heparin present in the reaction mixture. In either case, the reaction is continued to completion, as judged by cessation of nitrogen evolution.
  • the nitrous acid is prepared in situ by solution of sodium nitrite in cold acidic solution at a concentration of about 50 mM, and the reagent is used to treat the heparin at a concentration of about 100 mg/ml, at a pH of about 1.2 to about 1.8, preferably about 1.5.
  • the reaction is conducted at room temperature.
  • the mixture can be neutralized by addition of a suitable reagent at the desired stage of digestion; however, with respect to the present invention, the reaction is carried to completion.
  • depolymerization methods can also be used as long as they produce active components, i.e., components which (1) are di-, tetra- or hexasaccharides; (2) are sulfated so that the disaccharide or a disaccharide subunit contains at least two sulfates; (3) have substantial ability to stimulate the fibrin-dependent clot-dissolving activity of tPA or other proteins; and (4) have insignificant or no anticlotting activity.
  • active components i.e., components which (1) are di-, tetra- or hexasaccharides; (2) are sulfated so that the disaccharide or a disaccharide subunit contains at least two sulfates; (3) have substantial ability to stimulate the fibrin-dependent clot-dissolving activity of tPA or other proteins; and (4) have insignificant or no anticlotting activity.
  • the depolymerized saccharides can then be size-separated by a variety of means.
  • the mixture is chromatographed in a Biogel P10 system in which two columns are connected in tandem.
  • a system containing two 5-cm x 128-cm columns can accommodate as much as 160 ml of the polymerization mixture.
  • Fractions eluting from the columns are analyzed for saccharides using any convenient method; a particularly convenient method is the carbazol procedure for quantification of uronic acid content.
  • the peaks elute in reverse order of size, largest fragments first.
  • the identified, size-fractionated fractions from the size-separation protocol can then be analyzed for their activity with respect to tPA clot dissolution enhancement and can also be separated into their individual components.
  • Anion-exchange chromatography is conveniently used to separate molecules with differing charges.
  • HPLC high pressure liquid chromatography
  • Further separation by high pressure liquid chromatography (HPLC) permits the isolation of individual compounds.
  • HPLC separations are most conveniently performed on C18 columns run in the reversed phase ion-pairing mode or on polyethylene imine columns developed with salt gradients.
  • the mixture of disaccharides has been found to contain, as its major component, IdoA-AMan; minor
  • 2S 6S components are: GlcA-AMan and GlcA-AMan.
  • subunits also occur either at the reducing terminus, or internally, in the higher molecular weight saccharide oligo ers which are contained in the tetra-, hexa- and octasaccharide fractions.
  • the sulfates may be replaced by phosphate moieties using conventional technology.
  • di-, tetra- and higher molecular weight oligosaccharides can also be prepared synthetically. The synthetic approach generally involves preparation of an iduronic acid or glucuronic acid synthon and reaction therewith by a glycosamine reaction synthon.
  • the resulting disaccharide unit can be directly treated under the conditions of nitrous acid depolymerization to effect the conversion of the glucosamine residue to the anhydromannose.
  • the dimer however, prior to such conversion, is also useful in the invention.
  • the anhydromannose residue can further be reduced to convert the exocyclic aldehyde to an alcohol; these reduced compounds are also included within the invention. They can also be prepared by reduction of the depolymerization fragment mixtures.
  • the disaccharides can also be extended to form oligosaccharides containing any even number of saccharide units; this conversion can be followed by treatment to convert the reducing glycosamine to an anhydromannose or a reduced form thereof, if desired.
  • any of the uronic acid carboxyl residues can also be reduced to an alcohol.
  • These reduced forms of uronic acid saccha ⁇ rides are also included in the compounds of the invention.
  • the even-numbered saccharide may be reacted with either a uronic acid or glycosamine reaction synthon to provide polysaccharides containing any odd number of saccharide units. In the case of those saccharides having glycosamine residues at the reducing terminus, the above-mentioned conversions can also be employed.
  • the sulfate or phosphate moieties derivatized to the saccharide units may be added or exchanged to the finished oligomer, or may be introduced on the starting monomeric materials.
  • the synthetic saccharides must contain at least one disaccharide subunit which contains at least two sulfates. It is believed that the disulfated disaccharide subunit is responsible for binding to the kringle region of tPA. Although the larger saccharides appear to affect rate constant but not the Michaelis constant for the reaction catalyzed by tPA, the disaccharide affects both. This indicates that there must be an association of these saccharides with tPA.
  • the invention is directed to saccharides which lack anticoagulant activity and which contain 2-12 sugar units.
  • Within the saccharide must be a disaccharide uronic acid-glycosamine (or derivative thereof) subunit with at least two sulfate residues.
  • the uronic acid residue may either be in its reduced or nonreduced form.
  • Anticoagulant activity is assured to be absent in saccharides of less than 5 units, since this appears to be the minimum structure required; with regard to saccharides of greater length, assay for anticoagulation activity, for example by assessing ability to bind antithrombin III, is employed.
  • Preferred saccharide compounds of the invention include those wherein at least one uronic acid-glycosamine-derived unit contains at least two sulfates and is selected from the group consisting of:
  • oligosaccharides where at least one subunit is of the formula
  • IdoA-GlcNAc-IdoA-AMan 2S 6S 2S 6S including, for example,
  • the ability of the saccharides of the invention to enhance tPA activity is assessed as follows.
  • Various concentrations of plasminogen 40-200 nM are incubated with tPA (35 IU/ml) in the presence of the plasmin substrate D-Val-L-Leu-L-Lys-p-nitroanilide (VLK-pNA, 300 ⁇ M) in a buffer containing 50 mM Tris-HCl, 0.05% gelatin, and 0.01% Tween-80, pH 7.4.
  • VLK-pNA D-Val-L-Leu-L-Lys-p-nitroanilide
  • the reaction was monitored by change in absorbance due to liberation of P-nitroaniline from the plasmin substrate.
  • the assay is described in detail in Edelberg, J.M. , et al., Biochemistry (1990) 23:5906-5911.
  • the kinetic constants for plasminogen activation were determined by a double reciprocal plot of initial rates versus plasminogen concentrations in the absence of any test saccharides.
  • the activity with respect to tPA binding can also be conveniently assessed in a competitive assay using radiolabeled heparin in competition with the candidate fragment or compound.
  • this assay also gives a measure of physiological activity.
  • the invention compounds are administered systemically, either along with a clot-dissolving protease or as a means to enhance the activity of endogenous tPA or other fibrinolytic protease.
  • administration may be by any known systemic route, including injection intravenously, subcutaneously, intraperitoneally, or introduction using slow drug-release systems which are applied to the exterior to blood vessels, such as those described by Urquhart in U.S. patent 3,797,485.
  • administration by injection is preferred.
  • oral means of administration are preferred.
  • the short-chain oligosaccharides or disaccharides of the invention can readily be absorbed through the digestive tract into the bloodstream.
  • Formulations suitable for these modes of administration are known in the art, and a suitable compendium of formulations is found in Remington' s
  • Suitable formulations for injection include liquid formulations in buffers, physiological saline, or carriers such as Hank's Solution or Ringer's Solution, or the saccharides may be prepared in solid form and taken up in liquid suspension or solution for administration.
  • the invention saccharides are conveniently provided as syrups, tablets, capsules, powders, or can be added to foods or beverages to enhance acceptability and patient compliance.
  • the disaccharides or oligosaccharides can be included in juices, soft drinks, or milk-based confections such as milk shakes and eggnog, or can be added in recipes for solid foods such as pastries and pastas.
  • the oligosaccharides can be used to coat cereals or in frostings.
  • the saccharide compositions of the invention can be included in food and beverage compositions in a manner analogous to ordinary sugar.
  • the invention compositions may be administered as pure compounds or as mixtures of two or more of these active ingredients.
  • compositions may include the saccharide enhancers of fibrinolytic activity as the sole active ingredient or may also include the fibrinolytic protease, preferably tPA.
  • the subjects to whom the saccharides of the invention will be administered include those who are suffering from heart attack or other cardiovascular disturbance or at risk for these conditions. More particularly, the compositions of the invention may be used in the treatment of deep vein thrombosis, whether familial or nonfamilial, including when said thrombosis is surgically related. Also susceptible to treatment by the compositions of the invention are Atrophe blanche or livido vasculitis, systemic vasculitis, myocardial infarction, stroke and pulmonary emboli (which may, themselves, be a result of deep vein thrombosis) .
  • the invention compositions are useful in treating, therapeutically or prophylactically, patients with high levels of fibrinolytic inhibitors, including lipoprotein A.
  • Persons assessed with high levels of lipoprotein A are advantageously administered those embodiments of the invention compositions which are the disaccharide or tetrasaccharides as the activity of tPA is not inhibited in the presence of lipoprotein A when these embodiments are used as the stimulant.
  • use of heparin itself or of the invention compositions of higher molecular weight is less preferred.
  • Typical dosages are designed to result in concentrations of the saccharides of the invention in the bloodstream of approximately 20-100 ⁇ g/ml.
  • typical dosage ranges are on the order of 60-300 g. If administered intravenously, suitable dosages are in the range of 0.1-10 mg/kg/hour on a constant basis over a period of about 5-30 days. In particular, preferred dosage is about 0.3 mg/kg/hour or about 35 mg/hour or 840 mg/day for a 70 kg adult.
  • Antibodies immunoreactive with the saccharide compounds of the invention are useful in monitoring therapy and in immunoassays in general. These antibodies are prepared using conventional immunization protocols involving repeated administration of the saccharides to mammalian subjects such as rabbits, mice, rats, sheep, and the like. Antibody titers in the serum can be monitored using conventional immunoassays using the saccharides of the invention as antigen.
  • the administration of the saccharides should be in a form wherein they are conjugated to an antigenically neutral carrier to provide immunogenicity.
  • Suitable carriers include those conventional in the art, such as keyhole limpet hemacyanin (KLH) and various serum albumins.
  • KLH keyhole limpet hemacyanin
  • the VP6 protein of rotavirus has been shown to be a particularly effective carrier. Coupling to carrier is conducted by conventional means, including reductive amination, or usage of suitable linkers such as those available from Pierce Chemical Co. (Rockford, IL) .
  • the invention further includes the saccharides conjugated to the carriers employed in these immunization protocols, as well as the resulting antibodies.
  • Polyclonal antisera may be satisfactory for many utilities; preparation of monoclonal forms of these antibodies can also be effected using the standard Kohler-Milstein procedure with improvements, as is well known in the art.
  • the antibodies of the invention are thus useful in immunoassays, not only of the type described below involving competition between labeled composition and the analyte saccharide in the sample, but also for direct immunoassay of the saccharide. Alternate protocols involving direct assays are also of wide variety and well known.
  • the analyte bound to antibody is detected by means of an additional reactive partner which bears a label or other means of detection.
  • the binding of the antibodies of the invention to analyte can be detected by further reaction with a labeled preparation of these same antibodies or by labeled antibody immunoreactive with this preparation by virtue of species differences.
  • compositions of the invention may also be labeled using typical methods such as radiolabeling, fluorescent labeling, chromophores or enzymes, and used in a competitive assay for the amount of the saccharides of the invention in a biological sample.
  • Suitable protocols for competitive assays of analytes in biological samples are well known in the art, and generally involve treatment of the sample, in admixture with the labeled competitor, with a specific binding partner which is reactive with the analyte such as, typically, an immunoglobulin or fragment thereof.
  • the antibodies prepared according to the invention are useful for this purpose.
  • the binding of analyte and competitor to the antibody can be measured by removing the bound complex and assaying either the complex or the supernatant for the label. The separation can be made more facile by preliminary conjugation of the specific binding partner to a solid support.
  • Such techniques are well known in the art, and the protocols available for such competitive assays are too numerous and too well known to be set forth in detail here.
  • the labeled fragments can be utilized to detect the location of tPA in vivo, and, as tPA preferentially binds to blood clots, to localize blood clots, as well.
  • the conjugates are administered to the subject, preferably by injection, and the label detected by suitable radioscintographic means.
  • Appropriate labels for such detection include techneceum-99, iodine-131, and indium.
  • saccharides of the invention conjugated to solid supports are also useful for the purification of specifically binding moieties, including tPA, as well as for purification protocols for antibodies prepared as set forth above.
  • antibodies of the invention conjugated to solid support are useful for the purification of the invention saccharides.
  • Example 1 Preparation of Heparin Fragments Heparin (10 g) and 345 g sodium nitrite were dissolved in 80 ml water at pH 6. The pH of the solution was adjusted to 1.5 with 6N HC1 and maintained by dropwise addition of either 6N HCl or 2 M sodium carbonate. The reaction was maintained until completion was reached, as shown by the cessation of nitrogen evolution. In general, the time required was approximately 6 minutes. The pH was then adjusted to 8.5 with 2 M sodium carbonate and the mixture was centrifuged for 10 minutes at 8000 rpm in a Sorvall GSA rotor to remove a fine white precipitate which forms during the rise in pH. The supernatant is decanted, degassed under vacuum, and concentrated by lyophilization or rotary evaporation to a concentration of 300 mg heparin fragment/ml. The preparation process is scalable.
  • the saccharides elute sequentially by size, largest first; the last peak contains mostly disaccharides.
  • the disaccharide fraction was further fractionated by gel filtration on a Biogel P10 column (1 cm x 60 cm) to obtain unsulfated, onosulfated and disulfated disaccharides.
  • the fractions eluting from the Biogel P10 column were assayed for the ability to enhance tPA activity in the assay for conversion of plasminogen to plasmin described hereinabove with and without the addition of fragments prepared by CNBr digestion of fibrinogen to simulate fibrin stimulation.
  • the initial rate is 0.01 as determined above when no saccharide is added. Not shown in the figure are the results that this initial rate is the same (0.01) when lipoprotein A alone is added to the reaction mixture, and that the initial rate is increased to 0.04 when fibrinogen fragments alone are added. This is consistent with the known ability of fibrin to stimulate the tPA-catalyzed conversion of plasminogen to plasmin.
  • the saccharide fragment mixtures while much less capable of stimulating tPA, as compared to heparin in the absence of fibrinogen fragments (0.03-0.04, as initial rates), are comparable or more effective in this stimulation in the presence of fibrinogen fragments. This is significant as it more closely approximates physiological conditions.
  • lipoprotein A appears to make little difference when employed in the presence of the small fragments. As lipoprotein A has no effect in the absence of heparin (initial rate 0.01, comparable to the control) , heparin must mediate the inhibition by lipoprotein A. This effect is clearly not present in the case of the di- and tetrasaccharides. Presumably the smaller saccharides do not bind both tPA and lipoprotein A to the same saccharide backbone as may be the case for high molecular weight heparin.
  • FIG. 3A shows the V ⁇ values obtained in the plasminogen ⁇ plasmin assay described above in the presence of 50 ⁇ g/ml of each heparin fragment alone (shaded) or with 50 ⁇ g/ml of heparin fragment plus 50 nM LPA (striped) . (Fibrinogen fragments are not present.)
  • This figure clearly shows that lipoprotein A has no discernible affect on the initial reaction velocity when the disaccharide fragment is used; there is an almost negligible effect when the tetrasaccharide is used.
  • Figure 3B shows the effect of lipoprotein A increases dramatically. This is shown in another form in Figure 3B, as a percent of possible activity.
  • Guinea pigs, hamsters, or rabbits can be used. Radiolabeled fibrin, which accumulates in the lungs, is first injected, and tPA is administered. The appearance of labeled fibrin fragments in the blood is then measured, with and without the administration of the candidate saccharide. This jLn vivo model is useful in assessing the effects of the saccharide additives in in vivo contexts.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Les disaccharides ou oligosaccharides qui comprennent des sous-unités contenant au moins deux résidus et mélanges de fragments négativement chargés formés par dépolymérisation partielle ou complète de l'héparine par de l'acide nitreux sont capables de favoriser la capacité de l'activateur du plasminogène tissulaire endogène ou administré à dissoudre les caillots sanguins. Les unités de disaccharide qui contiennent, en particulier au moins deux résidus de sulfate, sont dépourvues d'activité anticoagulante, mais elles sont efficaces pour favoriser l'activité de dissolution de caillots de sang, spécifique à la fibrine, de l'activateur du plasminogène tissulaire.
PCT/US1992/002472 1991-03-29 1992-02-27 Modulation de l'activite de l'activateur du plasminogene tissulaire a l'aide de fragments d'heparine WO1992017506A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67774091A 1991-03-29 1991-03-29
US677,740 1991-03-29

Publications (1)

Publication Number Publication Date
WO1992017506A1 true WO1992017506A1 (fr) 1992-10-15

Family

ID=24719938

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1992/002472 WO1992017506A1 (fr) 1991-03-29 1992-02-27 Modulation de l'activite de l'activateur du plasminogene tissulaire a l'aide de fragments d'heparine

Country Status (2)

Country Link
AU (1) AU1680692A (fr)
WO (1) WO1992017506A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744457A (en) * 1995-03-31 1998-04-28 Hamilton Civic Hospitals Research Development Inc. Compositions and methods for inhibiting thrombogenesis
US5763427A (en) * 1995-03-31 1998-06-09 Hamilton Civic Hospitals Research Development Inc. Compositions and methods for inhibiting thrombogenesis
US5767269A (en) * 1996-10-01 1998-06-16 Hamilton Civic Hospitals Research Development Inc. Processes for the preparation of low-affinity, low molecular weight heparins useful as antithrombotics
US6001820A (en) * 1995-03-31 1999-12-14 Hamilton Civic Hospitals Research Development Inc. Compositions and methods for inhibiting thrombogenesis

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4944943A (en) * 1988-02-13 1990-07-31 Basf Aktiengesellschaft Mixture of a substance having thrombolytic activity and of an antithrombotic substance
US4945086A (en) * 1988-05-03 1990-07-31 The Board Of Trustees Of The Leland Stanford Junior University Smooth muscle cell growth inhibitor
US5023078A (en) * 1988-08-10 1991-06-11 Albert P. Halluin Plasminogen activator-heparin conjugates
US5032679A (en) * 1988-12-15 1991-07-16 Glycomed, Inc. Heparin fragments as inhibitors of smooth muscle cell proliferation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4944943A (en) * 1988-02-13 1990-07-31 Basf Aktiengesellschaft Mixture of a substance having thrombolytic activity and of an antithrombotic substance
US4945086A (en) * 1988-05-03 1990-07-31 The Board Of Trustees Of The Leland Stanford Junior University Smooth muscle cell growth inhibitor
US5023078A (en) * 1988-08-10 1991-06-11 Albert P. Halluin Plasminogen activator-heparin conjugates
US5032679A (en) * 1988-12-15 1991-07-16 Glycomed, Inc. Heparin fragments as inhibitors of smooth muscle cell proliferation

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ANALYTICAL BIOCHEMISTRY, Vol. 177, No. 2, issued March 1989, K. YOSHIDA et al., "Analysis of Unsaturated Disaccharides from Glycosaminogly curonan by High Performance Liquid Chromatography", pages 327-332. *
CHEST, Vol. 97, No. 4 (suppl), issued April 1990, TURPIE et al., "Tissue Plasminogen Activator (rt-PA) vs Heparin in Deep Vein Thrombosis", pages 1725-1755. *
FEBS LETTERS, Vol. 97, No. 1, issued January 1979, L. FRANSSON et al., "Relationship Between Anticoagulant Activity of Heparin and Susceptibility to Periodate Oxidation", pages 119-123. *
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, (USA), Vol. 86, issued May 1989, M.O. HOGG et al., "Fibrin Monomer Protects Thrombin from Inactivation by Heparin Antithrombin III: Implications for heparin Efficacy", pages 3619-3623. *
THE JOURNAL OF BIOLOGICAL CHEMISTRY, Vol. 2641, No. 3, issued 25 January 1989, T.C. WRIGHT, JR. et al., "Structural Determinants of Heparin's Growth Inhibitory Activity", pages 1534-1542. *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744457A (en) * 1995-03-31 1998-04-28 Hamilton Civic Hospitals Research Development Inc. Compositions and methods for inhibiting thrombogenesis
US5763427A (en) * 1995-03-31 1998-06-09 Hamilton Civic Hospitals Research Development Inc. Compositions and methods for inhibiting thrombogenesis
US6001820A (en) * 1995-03-31 1999-12-14 Hamilton Civic Hospitals Research Development Inc. Compositions and methods for inhibiting thrombogenesis
US5767269A (en) * 1996-10-01 1998-06-16 Hamilton Civic Hospitals Research Development Inc. Processes for the preparation of low-affinity, low molecular weight heparins useful as antithrombotics

Also Published As

Publication number Publication date
AU1680692A (en) 1992-11-02

Similar Documents

Publication Publication Date Title
US5250519A (en) Non-anticoagulant heparin derivatives
US5280016A (en) Non-anticoagulant heparin derivatives
US5032679A (en) Heparin fragments as inhibitors of smooth muscle cell proliferation
US5380716A (en) Sulfated polysaccharides as inhibitors of smooth muscle cell proliferation
US5696100A (en) Method for controlling O-desulfation of heparin and compositions produced thereby
US5296471A (en) Method for controlling o-desulfation of heparin and compositions produced thereby
Petitou et al. A synthetic antithrombin III binding pentasaccharide is now a drug! What comes next?
Pejler et al. Structure and antithrombin-binding properties of heparin isolated from the clams Anomalocardia brasiliana and Tivela mactroides.
US5013724A (en) Process for the sulfation of glycosaminoglycans, the sulfated glycosaminoglycans and their biological applications
US5795875A (en) Therapeutic methods of using O-desulfated heparin derivatives
WO1996006867A9 (fr) Methode de regulation de la o-desulfatation de l'heparine et des compositions qui en decoulent
CA2132750A1 (fr) Oligosaccharides presentant une grand affinite de liaison avec des facteurs de croissance
IE51166B1 (en) Oligosaccharides and oligosaccharide fractions having biological properties,processes for obtaining them and pharmaceutical compositions containing them
CA1180292A (fr) Oligosaccharides a chaine courte ayant des proprietes biologiques, preparation et utilisation comme medicaments
EP0582665A1 (fr) Polysaccharides sulfates en tant qu'inhibiteurs de la proliferation cellulaire dans les muscles lisses
HU219339B (en) Dermatan sulphate with low heparin or heparane sulphate content and pharmaceutical compositions comprising them
US20030023079A1 (en) Polysaccharides derived from K5 polysaccharide having high anticoagulant and antithrombotic activities and process for their preparation
WO1992017506A1 (fr) Modulation de l'activite de l'activateur du plasminogene tissulaire a l'aide de fragments d'heparine
WO1991015217A1 (fr) Oligosaccharides anticoagulants
WO1994008595A1 (fr) Utilisation d'heparine non anticoagulante dans le traitement des lesions ischemiques et consecutives a une perfusion

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA DK JP NO

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU MC NL SE

NENP Non-entry into the national phase

Ref country code: CA

122 Ep: pct application non-entry in european phase
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载